Paxil CR on the upswing
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
GlaxoSmithKline's Paxil CR has recaptured 41% of its previous new prescriptions since its late June relaunch, the firm says July 28. "We're up to 2.2% new Rx share," Pharmaceuticals President David Stout told investors during GSK's second quarter earnings call. Paxil CR Q2 sales dropped 75% to $42 mil. Part of GSK's relaunch efforts include a 30-day free trial program (1Pharmaceutical Approvals Monthly July 2005, In Brief)...
You may also be interested in...
Paxil CR resumes shipments
GlaxoSmithKline resumes shipments of Paxil CR, four months after manufacturing problems led to FDA's seizure of the product at distribution and production facilities. Sales reps will offer 30-day free trial vouchers to support reintroduction. Resupply of Avandamet, which also was seized by FDA, is projected to begin by mid-July...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.